Fig. 2. TP53^mut drive genomic instability and was associated with poor overall survival in therapy-related myeloid neoplasms (t-MN).

A Distribution of cases according to TP53^mut VAF; B Volcano plot comparing cytogenetic aberration and somatic mutations in TP53^mut and TP53^wt t-MN. Chromosomal aberrancies highly prevalent in TP53^mut (red) and somatic mutations enriched in TP53^wt cohort (green). Genomic changes that are not differentially expressed between the two groups are shown in gray color; C Frequency of cytogenetic aberrations or driver oncogenic gene mutations in TP53^wt and TP53^mut t-MN; D Number of co-mutations in TP53^wt and TP53^mut t-MN; E Overall survival (OS) of TP53^mut with VAF ≥10% or loss of TP53 locus was significantly poor compared to wild-type TP53 (TP53^wt) and TP53^mut with VAF < 10% t-MN; F Multivariate Cox-regression analysis of factors predicting overall survival in t-MN; G OS of TP53^mut t-MN according to VAF cut-offs; H Frequency of loss of heterozygosity (LOH) and copy neutral LOH (cnLOH) according to number of TP53^mut; I Density estimation of VAF of single-hit and multi-hit TP53^mut; J OS is equally poor in single- and multi-hit in t-MN.